ArticleJournal of neuro-oncology2025
Prognostic impact of second surgical resection in IDH wildtype recurrent glioblastoma following chemo-radiation therapy: a propensity score analysis cohort study.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Ferroptosis with Contributions from Apoptosis and Necroptosis in Porphyrazine III-Based Photodynamic Therapy of Primary Human Gliomas.Pharmaceutics · 2026Article
- From Data to Decision: Integrating Bioinformatics into Glioma Patient Stratification and Immunotherapy Selection.International journal of molecular sciences · 2026Review
- Proteomic profiling reveals dynamic regulation of vesicle trafficking across glioma grades.Journal of neuro-oncology · 2025Article
- Heterogeneity phenotypes in recurrent glioblastoma: a multimodal MRI-based spatial mapping framework for precision treatment.BMC medical imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal treatment for recurrent glioblastoma (rGBM) remains controversial. We explore the impact of re-surgical resection, compared to solely oncological treatment, in a cohort of isocitrate dehydrogenase (IDH) wild-type rGBM.
methodsA retrospective cohort study included adult patients diagnosed with IDHwt rGBM. At recurrence, patients recieved re-surgical resection (re-surgery group - RSG) or further oncological treatments (chemo-radiation group - CRG). Overall survival (OS) and progression-free survival (PFS) were analyzed. A Cox regression model was performed to identify variables related to outcomes. Furthermore, to minimize possible study design-related bias, a propensity score analysis was applied. Additionally, subgroup analysis to explore the role of adjuvant therapies was performed.
resultsIn a cohort of 104 patients with rGBM, 44 patients received re-surgical resection. Patients in RSG experienced a longer OS compared to CRG (21 vs. 12 months, p < 0.001); a shorter survival in the CRG was confirmed at the propensity score analysis (HR 2.16, p = 0.004). The median cohort PFS was 4 months. The PFS was similar between the RSG and CRG (6 vs. 4 months). The variables associated with OS were: age, subventricular zone involvement, repeated chemotherapy. The variables associated with PFS were: extent of resection at first surgery, MGMT methylation, no adjuvant therapies, and delayed radiotherapy. At the subgroup analysis, re-irradiation was not associated with OS or PFS benefit in the RSG; adjuvant chemo-radiation therapy offers a survival advantage compared to standard adjuvant chemotherapy in the CRG.
conclusionsRe-surgical resection offers a significant survival benefit compared to the sole adjuvant treatment in patients with IDHwt rGBM.
Indexed as
Identifiers
40423938What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.